FOLH1 and metastatic malignant neoplasm in the lymph nodes: Overall, lymph node metastases showed a stable PSMA-radioligand uptake at PET1 and PET2 (PET1: median SUVmax: 7.8 (Q1; 5.9; Q3: 10.4); PET2: median SUVmax 7.7 (Q1; 5.6; Q3: 16.0); p = 0.77 and PET1: median SUVmean: 5.0 (Q1: 3.6; Q3: 6.8); PET2: median SUVmean of 4.9 (Q1: 3.5; Q3: 10.2); p = 0.84).